| DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效 |
| |
| 引用本文： | 张俊萍,毛光华,史天良,杨晓玲,肖艳,张丽彬,冯慧晶,韩亚萍,智婷,王江涛,贾林梓.DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤生物治疗杂志,2011,18(4):424-429. |
| |
| 作者姓名： | 张俊萍 毛光华 史天良 杨晓玲 肖艳 张丽彬 冯慧晶 韩亚萍 智婷 王江涛 贾林梓 |
| |
| 作者单位： | 山西省肿瘤医院生物治疗科,山西太原,030013 |
| |
| 基金项目： | 山西省科技厅攻关项目资助（No.051096-2） |
| |
| 摘 要： | 目的:研究DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及安全性。方法:选取2008年8月至2010年1月就诊于山西省肿瘤医院的50例Ⅲ~Ⅳ晚期非小细胞肺癌患者,采用DC-CIK联合化疗多西他赛(docetaxel)+顺铂(cisplatin)]为联合治疗组;选取临床资料相近的同期进行单纯化疗(多西他赛+顺铂)的50例Ⅲ~Ⅳ晚期非小细胞肺癌患者为单纯化疗组,比较两组患者治疗后的免疫功能、近期疗效、1年生存率、生活质量,并观察DC-CIK细胞治疗的安全性。结果:成功培养患者的DC-CIK细胞,其中的CD3+CD8+、CD3+CD56+细胞比例较培养前显著提高(P<0.05)。联合治疗组患者治疗后外周血各T细胞亚群均无明显变化,IFN-γ水平显著升高(P<0.05);单纯化疗组患者治疗后外周血CD3+CD4+、CD3+CD8+、CD3-CD56+细胞比例下降(P<0.05),IL-2、TNF-α水平明显降低(P<0.05)。联合治疗组患者的DCR为78.0%,显著高于单纯化疗组的56.0%(P<0.05);联合治疗组患者1年生存率为50.0%,与单纯化疗组44.0%的差别无统计学意义(P>0.05)。联合治疗组患者的不良反应(包括骨髓抑制、恶心呕吐、周围神经毒性)明显轻于单纯化疗组(P<0.05),联合治疗组患者治疗后体力、食欲较单纯化疗组改善明显。结论:与单纯化疗相比,DC-CIK联合化疗治疗晚期非小细胞肺癌安全、有效,可以提高缓解率,延长生存期,改善患者的生活质量。
|
| 关 键 词： | DC-CIK 非小细胞肺癌 过继免疫细胞治疗 化疗 |
| 收稿时间： | 2011/4/12 0:00:00 |
| 修稿时间： | 2011/6/18 0:00:00 |
Dendritic cell-cytokine induced killer cells combined with chemotherapy in treatment of advanced non-small cell lung cancer patients: The clinical effectiveness |
| |
| ZHANG Jun-ping,MAO Guang-hu,SHI Tian-liang,YANG Xiao-ling,XIAO Yan,ZHANG Li-bin,FENG Hui-jing,HAN Ya-ping,ZHI Ting,WANG Jiang-tao and JIA Lin-zi.Dendritic cell-cytokine induced killer cells combined with chemotherapy in treatment of advanced non-small cell lung cancer patients: The clinical effectiveness[J].Chinese Journal of Cancer Biotherapy,2011,18(4):424-429. |
| |
| Authors: | ZHANG Jun-ping MAO Guang-hu SHI Tian-liang YANG Xiao-ling XIAO Yan ZHANG Li-bin FENG Hui-jing HAN Ya-ping ZHI Ting WANG Jiang-tao and JIA Lin-zi |
| |
| Institution: | Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China;Department of Biotherapy, Tumor Hospital of Shanxi Province, Taiyuan 030013, Shanxi, China |
| |
| Abstract: | |
| |
| Keywords: | DC-CIK non-small cell lung cancer adoptive immune cell therapy chemotherapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤生物治疗杂志》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤生物治疗杂志》下载免费的PDF全文 |
|
